NetraMark Holdings Inc. (AINMF)
| Market Cap | 88.38M |
| Revenue (ttm) | 431.60K |
| Net Income (ttm) | -2.84M |
| Shares Out | n/a |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,200 |
| Average Volume | 4,614 |
| Open | 1.070 |
| Previous Close | 0.932 |
| Day's Range | 1.050 - 1.070 |
| 52-Week Range | 0.114 - 1.250 |
| Beta | 1.81 |
| RSI | 42.28 |
| Earnings Date | Aug 12, 2025 |
About NetraMark Holdings
NetraMark Holdings Inc. develops artificial intelligence and machine learning solutions for the pharmaceutical industry in Canada. The company’s product suite comprises Netra Shatter; Netra Health Atlas; and NetraAi that is designed to help interact and explore with different perspective of the data for clinical trials. It provides NetraPlacebo module that analyzes past trial data to determine what drives placebo responses to guide inclusion/exclusion criteria; and Netra GPT module that offers insights from past clinical trials about the patien... [Read more]
Financial Performance
In 2024, NetraMark Holdings's revenue was 456,127, an increase of 410.97% compared to the previous year's 89,267. Losses were -3.33 million, -76.49% less than in 2023.
Financial numbers in CAD Financial StatementsNews
NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tra...
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transfo...
NetraMark Completes 2025 Annual General Meeting
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transfo...
NETRAMARK TO HOST SHAREHOLDER CONFERENCE CALL TO DISCUSS BUSINESS MOMENTUM
TORONTO , April 10, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transf...
NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION
TORONTO , April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transfo...
Netramark to Present at the 2024 Cantech Letter Conference in Toronto, ON
Toronto, Ontario--(Newsfile Corp. - October 2, 2024) - NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) (FSE: 8TV) (the "Company" or "NetraMark") a generative AI software leader in clinical trial an...
NETRAMARK, THE FIRST PUBLIC AI COMPANY TO LAUNCH CLINICAL TRIAL DE-RISKING TECHNOLOGY THAT INTEGRATES CHATGPT
TORONTO , May 16, 2023 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (Frankfurt: 8TV) (OTC: AINMF) announces the release of NetraGPT. Through newly developed algori...